Brandi Hilder

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Ajai Chari, Monique C. Minnema, Jesús G. Berdeja et al. · New England Journal of Medicine · 2022 · 576 citations · Full text

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Carolina Schinke, Cyrille Touzeau, Monique C. Minnema et al. · Journal of Clinical Oncology · 2023 · 84 citations

Clinical Immunology, Immunodeficiencies, Immunology +24

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder et al. · Cancer · 2017 · 72 citations · Full text

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Yaël C. Cohen, Hila Magen, Moshe E. Gatt et al. · New England Journal of Medicine · 2025 · 70 citations

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, Jesús G. Berdeja, Albert Oriol et al. · Blood · 2020 · 59 citations